Identification of Novel Imidazo[1,2-a]pyridine Inhibitors Targeting M. tuberculosis QcrB
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. Through the use of high throughput whole cell screening of an extensive compound library a number of imidazo[1,2-a]pyridine (IP) compounds were obtained as potent lead molecules active against M. tuberculosis and Mycobacterium bovis BCG. The IP inhibitors (1-4) demonstrated minimum inhibitory concentrations (MICs) in the range of 0.03 to 5 µM against a panel of M. tuberculosis strains. M. bovis BCG spontaneous resistant mutants were generated against IP 1, 3, and 4 at 5× MIC and subsequent whole genome sequencing identified a single nucleotide polymorphism (937)ACC>(937)GCC (T313A) in qcrB, which encodes the b subunit of the electron transport ubiquinol cytochrome C reductase. This mutation also conferred cross-resistance against IP 1, 3 and 4 demonstrating a common target. Gene dosage experiments confirmed M. bovis BCG QcrB as the target where over-expression in M. bovis BCG led to an increase in MIC from 0.5 to >8 µM for IP 3. An acute murine model of TB infection established bacteriostatic activity of the IP series, which await further detailed characterization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The QcrB subunit has been recently shown to be the target of novel imidazo[1,2-a]pyridine inhibitors that are active against M. tuberculosis at low micromolar concentrations (73).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 1×
“Aligned BAM files were supplied as input to the samtools mpileup command using the command-line modifiers ‘‘-C50 -D -S –E’’ and otherwise default settings [30].”
MethodFast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Woese, C. R. (1987) · Microbiological Reviews · doi:10.1128/mr.51.2.221-271.1987 · Cited by 5,042
Genes required for mycobacterial growth defined by high density mutagenesis
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03425.x · Cited by 2,544 · cited 2×
“According to TraSH analysis, qcrB is an essential gene [35,36,37].”
BackgroundA Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 2×
“identified utilizing a whole cell phenotypic HTS campaign of a library of more than 70,000 compounds against Mycobacterium smegmatis [11,12,13].”
MethodPossible molecular mechanisms of the protonmotive function of cytochrome systems
Mitchell, P. (1976) · Journal of Theoretical Biology · doi:10.1016/0022-5193(76)90124-7 · Cited by 1,268 · cited 1×
“as it functions by binding to the Qi site, proximal to the BH heme, inhibiting oxidation of the cytochrome b subunit [50].”
BackgroundThe challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042 · cited 2×
“era where TB is untreatable, the discovery of unique drug targets and novel inhibitory compounds can be considered invaluable in terms of meeting the current and future therapeutic needs to relieve the burden of TB cases worldwide [4].”
BackgroundCrystal Structure of the Cytochrome bc 1 Complex from Bovine Heart Mitochondria
Xia, D., Yu, C.-A., Kim, H., Xia, J.-Z., Kachurin, A. M., Zhang, L., Yu, L., & Deisenhofer, J. (1997) · Science · doi:10.1126/science.277.5322.60 · Cited by 946 · cited 1×
“the structure of a myxothiazol-bound cytochrome bc1 complex [51] found the substitution did not fall within the myxothiazol”
BackgroundComprehensive identification of conditionally essential genes in mycobacteria
Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231275498 · Cited by 616 · cited 2×
“According to TraSH analysis, qcrB is an essential gene [35,36,37].”
Background
Cited by
Items 101–180 of 180
Soto, R., Pérez‐Herrán, E., Rodríguez, B., Duma, B. M., Cacho, M., Mendoza-Losana, A., Lelièvre, J., Barros-Aguirre, D., Ballell, L., Cox, L. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31157-3 · Cited by 25
Self-citationEnergetics of Respiration and Oxidative Phosphorylation in Mycobacteria
Cook, G. M., Hards, K., Vilchèze, C., Hartman, T. E., & Berney, M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch20 · Cited by 24
Kanvatirth, P., Jeeves, R. E., Bacon, J., Besra, G. S., & Alderwick, L. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213713 · Cited by 22
Self-citationPreparation and Evaluation of Potent Pentafluorosulfanyl‐Substituted Anti‐Tuberculosis Compounds
Moraski, G. C., Bristol, R., Seeger, N., Boshoff, H. I., Tsang, P. S., & Miller, M. J. (2017) · ChemMedChem · doi:10.1002/cmdc.201700170 · Cited by 22
Clustering and recent transmission of Mycobacterium tuberculosis in a Chinese population
Xu, G., Mao, X., Wang, J., & Pan, H. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s156534 · Cited by 21
“For example, the ETRB locus was associated with INH resistance, 26 and the MIRU20 locus was associated with EMB resistance.”
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis
Appetecchia, F., Consalvi, S., Scarpecci, C., Biava, M., & Poce, G. (2020) · Pharmaceuticals · doi:10.3390/ph13090227 · Cited by 23
Ekins, S., Madrid, P. B., Sarker, M., Li, S.-G., Mittal, N., Kumar, P., Wang, X., Stratton, T. P., Zimmerman, M. D., Talcott, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141076 · Cited by 22
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon
Kufa, M., Finger, V., Kovar, O., Soukup, O., Torruellas, C., Roh, J., & Korábečný, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.01.023 · Cited by 27
“Telacebec was recognized as a part of the optimization study on imidazo[1,2-a ]pyridine-3-carboxamides, identified through high-throughput screening of compounds against intracellular Mtb 138,139 .”
Genetic Approaches to Facilitate Antibacterial Drug Development
Schnappinger, D. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021139 · Cited by 24
Onajole, O. K., Lun, S., Yun, Y. J., Langue, D. Y., Jaskula‐Dybka, M., Flores, A., Frazier, E., Scurry, A. C., Zavala, A., Arreola, K. R., et al. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13739 · Cited by 19
One-pot synthesis of tetracyclic fused imidazo[1,2-a]pyridines via a three-component reaction
Yang, B. H., Tao, C., Shao, T., Gong, J., & Che, C. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.145 · Cited by 19
New antituberculosis drugs targeting the respiratory chain
Li, Q., & Lu, X. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.04.007 · Cited by 17
Bown, L., Srivastava, S. K., Piercey, B. M., McIsaac, C. K., & Tahlan, K. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9997-3 · Cited by 16
Li, L., Li, Z., Liu, M., Shen, W., Wang, B., Guo, H., & Lu, Y. (2015) · Molecules · doi:10.3390/molecules21010049 · Cited by 17
Anti-tubercular drug discovery: in silico implications and challenges
Mehra, R., Khan, I. A., & Nargotra, A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.028 · Cited by 14
Murnane, R., Zloh, M., Tanna, S., Allen, R. H., Santana-Gomez, F., Parish, T., & Brucoli, F. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106659 · Cited by 14
“…to, 2-(quinolin-4-yloxy)acetamides (QOAs) [7 – 12], lansoprazole [13], imidazo[4,5-c ]pyridine [14] and imidazo[1,2-a ]pyri-dines amides (IPAs) [15], e.g., Q203 [16,17] and ND-008454 [18], morpholino thiophenes [19], anilinyl-analogues of phenox-yalkylbenzimidazoles (PABs) [20] and…”
Quach, D., Sharp, M. D., Ahmed, S., Ames, L., Bhagwat, A., Deshpande, A., Parish, T., Pogliano, J., & Sugie, J. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2419813122 · Cited by 14
Li, L., Wang, A., Wang, B., Liu, M., Lv, K., Tao, Z., Ma, C., Ma, X., Han, B., Wang, A., et al. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.07.038 · Cited by 14
Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds
Anagani, B., Singh, J., Bassin, J. P., Besra, G. S., Benham, C. D., Reddy, T. R. K., Cox, J. A. G., & Goyal, M. (2020) · The Cell Surface · doi:10.1016/j.tcsw.2020.100041 · Cited by 15
Self-citationCook, G. M., Hards, K., Dunn, E. A., Heikal, A., Nakatani, Y., Greening, C., Crick, D. C., Fontes, F. L., Pethe, K., Hasenoehrl, E., et al. (2017) · ASM Press eBooks · doi:10.1128/9781555819569.ch14 · Cited by 18
Next-generation antimicrobials: from chemical biology to first-in-class drugs
Ang, M. L. T., Murima, P., & Pethe, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0645-0 · Cited by 14
McNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 15
Advances in Drug Discovery and Development for Pediatric Tuberculosis
Hoagland, D. T., Zhao, Y., & Lee, R. E., Jr. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150722101723 · Cited by 16
Open Lab as a source of hits and leads against tuberculosis, malaria and kinetoplastid diseases
Ballell, L., Strange, M., Cammack, N. C., Fairlamb, A. H., & Borysiewicz, L. K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.51 · Cited by 13
Self-citationCui, Y., Lanne, A., Peng, X., Browne, E., Bhatt, A., Coltman, N. J., Craven, P. G. E., Cox, L. R., Cundy, N. J., Dale, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01643 · Cited by 11
Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues
Rombouts, J. A., Veenboer, R. M. P., Villellas, C., Lü, P., Ehlers, A. W., Andries, K., Koul, A., Lill, H., Ruijter, E., Orrù, R. V. A., et al. (2016) · RSC Advances · doi:10.1039/c6ra22693k · Cited by 12
Cytochrome bc1-aa3 Oxidase Supercomplex As Emerging and Potential Drug Target Against Tuberculosis
Sindhu, T., & Pal, D. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210928152512 · Cited by 12
Targeting the cytochrome bc1 complex for drug development in M. tuberculosis: review
Wani, M. A., & Dhaked, D. K. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10335-y · Cited by 11
Recent advancements in the quest of benzazoles as anti-Mycobacterium tuberculosis agents
Patel, K. I., Saha, N., Dhameliya, T. M., & Chakraborti, A. K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108093 · Cited by 10
Burke, C., Abrahams, K. A., Richardson, E. J., Loman, N. J., Alemparte, C., Lelièvre, J., & Besra, G. S. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00048 · Cited by 10
Self-citationInhibitors of enzymes in the electron transport chain of Mycobacterium tuberculosis
Thompson, A. M., & Denny, W. A. (2019) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2019.05.001 · Cited by 14
Tembe, N., Machaba, K. E., Ndagi, U., Kumalo, H. M., & Mhlongo, N. N. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04993-w · Cited by 9
Investigation of quinolone‐tethered aminoguanidine as novel antibacterial agents
Angula, K. T., Legoabe, L. J., Jordaan, A., Warner, D. F., & Beteck, R. M. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200172 · Cited by 9
Microwave Assisted Synthesis of Disubstituted Imidazo[1,2-a]pyridine-3-carboxylic Acid Esters
Liu, M., Zhang, Q., Li, L., Wu, Z., Li, Z., & Guo, H. (2015) · Heterocycles · doi:10.3987/com-15-13299 · Cited by 9
Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík, I., Cizmárik, J., Kováč, G., Pecháčová, M., & Hudecová, L. (2021) · Česká a slovenská farmacie · doi:10.5817/csf2021-5-164 · Cited by 12
Dylong, A., Sowa, M., Goldeman, W., Ślepokura, K. A., Duczmal, M., Wojciechowska, A., & Matczak‐Jon, E. (2014) · Polyhedron · doi:10.1016/j.poly.2014.03.004 · Cited by 9
Pushkaran, A. C., Biswas, R., & Mohan, C. G. (2019) · Challenges and advances in computational chemistry and physics · doi:10.1007/978-3-030-05282-9_10 · Cited by 11
Finding New Ways to Combat Multidrug-Resistant Tuberculosis
Faridgohar, M. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0353 · Cited by 9
New Triazolopyrimidines with Improved Activity against Mycobacterium tuberculosis
Pogula, S. R., Deshpande, A., Greve, E., Chowdhury, S., & Parish, T. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00073 · Cited by 7
Bokosi, F. R. B., Beteck, R. M., Jordaan, A., Seldon, R., Warner, D. F., Tshiwawa, T., Lobb, K. A., & Khanye, S. D. (2021) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4340 · Cited by 7
Liu, R., Marshall, K., Ma, R., Pham, K. L. T., Shetye, G. S., Liu, Z., Cho, S., Jeong, H., Franzblau, S. G., Moraski, G. C., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106074 · Cited by 8
The Emerging Landscape of Tubercular Targets: A Medicinal Chemistry Approach
Shaik, B. B., Moodley, K., Ghumran, S., Bala, M. D., Singh, P., & Karpoormath, R. V. (2025) · Medicinal Research Reviews · doi:10.1002/med.22100 · Cited by 8
“In 2012, imidazopyridine amide 87 (Figure 27) was identified and exhibited a MIC of 0.03 µM [184].”
InfluentialKhan, A. A., Poojary, S. S., Bhave, K., Nandan, S., Iyer, K. R., & Coutinho, E. C. (2022) · ACS Omega · doi:10.1021/acsomega.2c01613 · Cited by 7
Cheng, X., Jiang, C., Zhang, M., Xia, D., Chu, L., Wen, Y., Zhu, M., & Jiang, Y.-G. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00378 · Cited by 7
On drug discovery against infectious diseases and academic medicinal chemistry contributions
Janin, Y. L. (2022) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.18.141 · Cited by 7
Hamd, A. H., & Al-Lami, N. (2023) · Iraqi Journal of Science · doi:10.24996/ijs.2023.64.7.1 · Cited by 6
Phelan, J. E., den Heede, K. V., Masyn, S., Verbeeck, R., Clark, T. G., Lamprecht, D. A., Koul, A., & Wall, R. J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75818-y · Cited by 6
Nandhagopal, M., Mala, R., Somarathinam, K., Dhakshinamurthy, D., Mathivanan, N., Vijayan, P., & Shankar, M. M. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03780-w · Cited by 8
“…antifungal as well as anthelmintic agents, the promising drug candidate for antitumor therapy, antiulcer agents, M. tuberculosis and M. bovis , anticonvulsant studies, anti-protozoal agents, analgesic and anti-inflammatory properties (Gueiffier et al. 1996; Goel et al. 2016; Abrahams et al. 2012).”
Recent Progress on the Development of Novel Antitubercular Agents from Whole-Cell Screening Hits
Yokokawa, F. (2014) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.72.1239 · Cited by 6
Jadhav, B. S., Kenny, R. S., Nivid, Y., Mandewale, M. C., & Yamgar, R. (2016) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2016.64006 · Cited by 6
Anti-tubercular derivatives of rhein require activation by the monoglyceride lipase Rv0183
Abrahams, K. A., Hu, W., Li, G., Lu, Y., Richardson, E. J., Loman, N. J., Huang, H., & Besra, G. S. (2020) · The Cell Surface · doi:10.1016/j.tcsw.2020.100040 · Cited by 5
Self-citationBurke, C., Jankute, M., Moynihan, P. J., del Río, R. G., Li, X., Esquivias, J., Lelièvre, J., Cox, J. A. G., Sacchettini, J. C., & Besra, G. S. (2020) · FASEB BioAdvances · doi:10.1096/fba.2020-00022 · Cited by 6
Self-citationBond, A. N., Orzechowski, M., Zhang, S., Ben-Zion, I., Lemmer, A., Garry, N., Lee, K., Chen, M. J., Delano, K., Gath, E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64662-x · Cited by 9
Onajole, O. K., Lun, S., Kishore, D. R., Savić, A., Morales, A., Guzman, A., Schmidt, E., Lazzara, A., Fajardo, G. D., Jamieson, D. P., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130447 · Cited by 3
Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery
Mukherjee, R., Anup, C. P., & Banerjee, M. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.06.004 · Cited by 3
Bacterial c-type cytochromes and pathogenicity
Wilson, A. C. (2015) · European Journal of BioMedical Research · doi:10.18088/ejbmr.1.1.2015.pp17-21 · Cited by 4
Lessons Learned in TB Drug Discovery: An Industrial Chemist’s Perspective
Jiřiček, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.83 · Cited by 3
Ommi, O., Bhalerao, H. A., Malik, P., Ali, J., Saxena, D., Nanduri, S., Sonti, R., Dasgupta, A., Chopra, S., & Yaddanapudi, V. M. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118341 · Cited by 2
Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc 1 Complex
Gries, R., Molin, M. D., Chhen, J., van Gumpel, E., Dreyer, V., Niemann, S., & Rybniker, J. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00251-23 · Cited by 2
Discovery and development of new antibacterial drugs
Elassal, E. S., Fahmy, A., Saad, A. N. M., Ali, A. H., Elshenety, A. H., Badr, O. A., Amer, A. N., Fouda, W. M., & Elshaier, Y. A. M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18866-4.00012-2 · Cited by 2
Zazharskyi, V. V., Davydenko, P. О., & Bihdan, O. A. (2020) · Ukrainian Journal of Ecology · doi:10.15421/2020_274 · Cited by 2
Bond, A. N., Orzechowski, M., Zhang, S., Ben-Zion, I., Lemmer, A., Garry, N., Lee, K., Chen, M. J., Delano, K., Gath, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.15.638392 · Cited by 2
Hit Compounds and Associated Targets in Intracellular Mycobacterium tuberculosis
Tsui, C. K. M., Sorrentino, F., Narula, G. S., Mendoza-Losana, A., del Río, R. G., Pérez‐Herrán, E., Moure, A. L., Bojang, A. L., Zheng, X., Remuiñán, M. J., et al. (2022) · Molecules · doi:10.3390/molecules27144446 · Cited by 2
Self-citationThe Challenges of Antitubercular Drug Discovery
Prates, J. L. B., Fernandes, G., Rodríguez-Silva, C. N., & dos Santos, J. L. (2023) · Integrated science · doi:10.1007/978-3-031-15955-8_23 · Cited by 1
Systematic Review of New Trends in Antitubercular Synthesis and Analysis
Dackouo, B., & Arama, D. P. (2019) · Journal of Materials Science and Chemical Engineering · doi:10.4236/msce.2019.71001 · Cited by 1
Lanne, A., Cui, Y., Browne, E., Craven, P. G. E., Cundy, N. J., Coltman, N. J., Dale, K., Feula, A., Frampton, J., Goff, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.03.281170 · Cited by 1
Coulibaly, S., Evrard, A., Kumar, A., & Sissouma, D. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-trm05 · Cited by 1
Coulibaly, S., Evrard, A., Kumar, A., & Sissouma, D. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-trm05-v2 · Cited by 1
Rethinking Drug Discovery and Targeting After the Genomic Revolution
Chejara, D. R., Badhe, R. V., Kumar, P., Choonara, Y. E., Tomar, L. K., Tyagi, C., & Pillay, V. (2018) · Springer eBooks · doi:10.1007/978-981-10-7506-3_1
Phenotypic Screening for Drug Discovery in Tuberculosis
Delorme, V. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00198
The outcome of different forms and regiments of antituberculous drugs in Assiut Governorate
Ghanem, M., Makhlouf, H. A., Hasan, A.-A., & Kelada, D. S. (2021) · Journal of Current Medical Research and Practice · doi:10.4103/jcmrp.jcmrp_65_20
Sangeeta, S. T. (2021) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/152336
Sindhu, T., Sundarraj, R., Jeyakanthan, J., & Pal, D. (2023) · Research Square · doi:10.21203/rs.3.rs-2903522/v1
Treatment of Drug-Resistant Pulmonary Tuberculosis
Deng, G., Liu, M.-N., Fu, L., Zhang, N., Zheng, J. Y., Chen, Q.-Q., Chen, C., Li, T.-X., Lu, S., & Lu, H. (2023) · Springer eBooks · doi:10.1007/978-981-99-8339-1_15
Wu, J., Chaudhuri, S., Feid, S. C., Joshi, H., Pan, M., Kawaji, Q., Liu, G., & Javid, B. (2026) · mBio · doi:10.1128/mbio.02056-26
Zhang, W., Wu, K., Zheng, C., Wang, G., Zhong, W., & Ling, F. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00273k
Deshpande, A., & Parish, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.25.747121
BindingDB (2024) · UC San Diego · doi:10.7270/q2fr01td
Metadata
- Authors
- Abrahams, K. A., Cox, J. A. G., Spivey, V. L., Loman, N. J., Pallen, M. J., Constantinidou, C., Fernández, R., Alemparte, C., Remuiñán, M. J., Barros, D., Ballell, L., & Besra, G. S.
- Affiliations
- University of Birmingham (GB)
- GlaxoSmithKline (Spain) (ES)
- Corresponding author
- Besra, Gurdyal S.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-31
- Volume
- 7
- Issue
- 12
- Pages
- e52951
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3534098
- OpenAlex
- W1974074976
- Cited by
- 177
- References
- 53
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 11 · 2020: 18 · 2019: 16 · 2018: 17 · 2017: 16 · 2016: 19 · 2015: 22 · 2014: 20 · 2013: 3
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Funders
- University of Warwick
- European Commission (261378, 2007–2013, FP7 2007-2013)
- Biotechnology and Biological Sciences Research Council (1112080)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and Biological Evaluation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- imidazo[1,2-a]pyridines, Mycobacterium tuberculosis, Mycobacterium bovis BCG, drug resistance, cross-resistance, gene dosage, lead compound identification, murine tuberculosis model, tuberculosis drug discovery
- MeSH terms
- Animals, Antitubercular Agents, Dogs, Humans, Microbial Sensitivity Tests, Microsomes, Liver, Mycobacterium bovis, Mycobacterium tuberculosis, Pyridines, Tuberculosis, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.